Wyeth 2Q Revenues: $5.2 billion (+9%) 2Q Earnings: $1 billion (+9%) YTD Revenues: $10 billion (+8%) YTD Earnings: $2.2 billion (+6%) Comments: Pharmaceuticals revenue growth of 11% for quarter was driven by Enbrel and Prevnar. Enbrel sales (outside the U.S. and Canada) were $370 million, up 36% and Prevnar sales were $518 million, an increase of 60%. The company submitted two NDAs in the quarter, for bazedoxifene (osteoporosis) and desvenlafaxine succinate (vasomotor sympto...